Drugs / VM-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05276076 | Nov 2022 → Nov 2024 | graft versus host disease | ViGenCell Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Betta Pharmaceuticals Co., Ltd. | Results 贝达药业四项研究成果亮相2025AACR年会 bettapharma.com ↗
这一组合疗法不仅改变了肿瘤微环 境，并具有精准靶向性和旁观者效应，显著提高了治疗效果，为癌症患者，特别是那些对现有治疗药物耐药或无药可医的患者，提供了全新的治疗选择。 |
| 2020-12-01 | ViGenCell Inc. | Regulatory [보도자료] 바이젠셀, 표준치료법 없는 이식편대숙주질환 치료제 'VM-001(GVHD)' 임상1/2a 상 승인(2020.11) vigencell.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Betta Pharmaceuticals Co., Ltd. | 贝达药业四项研究成果亮相2025AACR年会 bettapharma.com ↗ |
| 2020-12-01 | ViGenCell Inc. | [보도자료] 바이젠셀, 표준치료법 없는 이식편대숙주질환 치료제 'VM-001(GVHD)' 임상1/2a 상 승인(2020.11) vigencell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05276076 ↗ |
| Modality | Cell therapy | “Biological: VM-001 1X10^6 cells/kg” NCT05276076 ↗ |
| Route | Intravenous | “Administration: Inject intravenously single dose” NCT05276076 ↗ |